Alto Neuroscience Reports Third Quarter 2026 Financial Results and Recent Business Highlights
Business Wire•10/11/2026•16:05 ET
0
Key Highlights
- ➤$100.0 million financing completed at $26.48 per share, generating approximately $94.6 million net proceeds
- ➤Cash, cash equivalents, and restricted cash reached $319.8 million, funding planned operations through 2030
- ➤PACE-1 enrollment remains on track, with topline treatment-resistant depression data expected in 2H 2027
- ➤PACE-3 monotherapy Phase 3 trial initiation expected in 2H 2027, pending FDA alignment
- ➤Third-quarter net loss widened to $25.1 million from $14.2 million year over year
Expert Statements
Amit Etkin, Founder and Chief Executive Officer of Alto Neuroscience
“During the third quarter, we continued to advance our clinical programs and strengthened our financial position ahead of a milestone-rich 2027. PACE-1 remains on track, and our recent financing has enabled us to expand the ALTO-207 Phase 3 development plans to include both monotherapy and adjunctive trials, aimed at supporting a broad label in TRD.”
Alto Neuroscience Reports Third Quarter 2026 Financial Results and Recent Business Highlights
– PACE-1 trial of ALTO-207 in treatment-resistant depression (TRD) on track; topline data in 2H 2027 –
Get started
Create a free account to read the full story.